Document is current
Any future updates will be listed below
-
Authors
Leu, Jocelyn H.
Shiff, Natalie J.
Clark, Michael
Bensley, Karen
Lomax, Kathleen G.
Berezny, Katherine
Nelson, Robert M.
Zhou, Honghui
Xu, Zhenhua
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02277444 at ClinicalTrials.govnct01090427 at ClinicalTrials.govDocuments that mention this clinical trial
Intravenous Golimumab in Patients with Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis and Subcutaneous Ustekinumab in Patients with Juvenile Psoriatic Arthritis: Extrapolation of Data from Studies in Adults and Adjacent Pediatric Populations
https://doi.org/10.1007/s40272-022-00533-y
nct02698475 at ClinicalTrials.govDocuments that mention this clinical trial
Intravenous Golimumab in Patients with Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis and Subcutaneous Ustekinumab in Patients with Juvenile Psoriatic Arthritis: Extrapolation of Data from Studies in Adults and Adjacent Pediatric Populations
https://doi.org/10.1007/s40272-022-00533-y
Documents that mention this clinical trial
Intravenous Golimumab in Patients with Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis and Subcutaneous Ustekinumab in Patients with Juvenile Psoriatic Arthritis: Extrapolation of Data from Studies in Adults and Adjacent Pediatric Populations
https://doi.org/10.1007/s40272-022-00533-y
-
Funding
Funding for this research was provided by:
Janssen Research and Development
- License Information
-
More Information
Article History
Accepted: 16 August 2022
First Online: 28 September 2022
Declarations
:
: This work was supported by Janssen Research & Development, LLC. Janssen Research & Development, LLC had a role in the trial design; collection, analysis, and interpretation of data; writing of the report; and the decision to submit the article for publication.
: Jocelyn H. Leu, Michael Clark, Karen Bensley, Kathleen G. Lomax, Katherine Berezny, and Zhenhua Xu are employees of Janssen Research & Development, LLC, a subsidiary of Johnson & Johnson, and may own stock in Johnson & Johnson. Honghui Zhou was an employee of Janssen Research & Development, LLC, a subsidiary of Johnson & Johnson, at the time the work was conducted and may own stock in Johnson & Johnson; Dr. Zhou is currently an employee at Elevar Therapeutics, Inc, Salt Lake City, UT, USA. Natalie J. Shiff is an employee of Janssen Scientific Affairs, LLC, a subsidiary of Johnson & Johnson; received salary support from the Childhood Arthritis and Rheumatology Research Alliance within the past 3 years; and owns or has owned stock in AbbVie, Gilead, Iovance, Johnson & Johnson, Novo-Nordisc, and Pfizer within the past 3 years. Robert M. Nelson is an employee of Johnson & Johnson and owns stock in Johnson & Johnson.
: All trials included in these analyses were conducted and reported in accordance with the ethical principles originating in the Declaration of Helsinki and in accordance with International Council for Harmonisation Good Clinical Practice guidelines, applicable regulatory requirements, and in compliance with the respective protocols.
: All participants or legal guardians of participants in the clinical trials included in these analyses provided written informed consent.
: Not applicable.
: The data-sharing policy of Janssen Pharmaceutical Companies of Johnson & Johnson is available at . As noted on this site, requests for access to the trial data can be submitted through Yale Open Data Access (YODA) Project site at .
: Not applicable.
: Conceptualization: JHL, NJS, KBen, KGL, KBer, RMN, HZ, ZX. Methodology: JHL, MC, KBen, KGL, KBer, RMN, HZ, ZX. Data collection and/or analysis: JHL, NJS, MC, KBen, KGL, KBer, HZ, ZX. Data interpretation: JHL, NJS, MC, KBen, KGL, KBer, RMN, HZ, ZX. Manuscript preparation, review, and editing: All authors. All authors approved the final version of the manuscript for publication.
